Search Results - "Vos, Joris L"

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma by Valero, Cristina, Golkaram, Mahdi, Vos, Joris L, Xu, Bin, Fitzgerald, Conall, Lee, Mark, Kaplan, Shannon, Han, Catherine Y, Pei, Xin, Sarkar, Reith, Boe, Lillian A, Pandey, Abhinav, Koh, Elizabeth S, Zuur, Charlotte L, Solit, David B, Pawlowski, Traci, Liu, Li, Ho, Alan L, Chowell, Diego, Riaz, Nadeem, Chan, Timothy A, Morris, Luc Gt

“…BACKGROUNDRecurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is generally an incurable disease, with patients experiencing median…”
Get full text

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors by Gil-Jimenez, Alberto, van Dijk, Nick, Vos, Joris L., Lubeck, Yoni, van Montfoort, Maurits L., Peters, Dennis, Hooijberg, Erik, Broeks, Annegien, Zuur, Charlotte L., van Rhijn, Bas W. G., Vis, Daniel J., van der Heijden, Michiel S., Wessels, Lodewyk F. A.

“…Immune checkpoint inhibitors (ICI) can achieve remarkable responses in urothelial cancer (UC), which may depend on tumor microenvironment (TME)…”
Get full text

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma by Vos, Joris L., Elbers, Joris B. W., Krijgsman, Oscar, Traets, Joleen J. H., Qiao, Xiaohang, van der Leun, Anne M., Lubeck, Yoni, Seignette, Iris M., Smit, Laura A., Willems, Stefan M., van den Brekel, Michiel W. M., Dirven, Richard, Baris Karakullukcu, M., Karssemakers, Luc, Klop, W. Martin C., Lohuis, Peter J. F. M., Schreuder, Willem H., Smeele, Ludi E., van der Velden, Lilly-Ann, Bing Tan, I., Onderwater, Suzanne, Jasperse, Bas, Vogel, Wouter V., Al-Mamgani, Abrahim, Keijser, Astrid, van der Noort, Vincent, Broeks, Annegien, Hooijberg, Erik, Peeper, Daniel S., Schumacher, Ton N., Blank, Christian U., de Boer, Jan Paul, Haanen, John B. A. G., Zuur, Charlotte L.

“…Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a…”
Get full text

Patterns of immune equilibrium and escape in indolent and progressing tumors by Pandey, Abhinav, Linxweiler, Maximilian, Kuo, Fengshen, Marti, Jennifer L., Roman, Benjamin, Ehdaie, Behfar, Vos, Joris L., Morris, Luc G.T.

“…By comparing indolent/slowly progressing with aggressive/rapidly progressing tumor types, Pandey et al. identify human evidence of immune equilibrium in…”
Get full text

Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma by Desilets, Antoine, Vos, Joris L, Katabi, Nora, Kuo, Fengshen, Nadeem, Zaineb, Linxweiler, Maximilian, Ostrovnaya, Irina, Baxi, Shrujal, Dunn, Lara A, Sherman, Eric J, Pfister, David G, Morris, Luc G T, Ho, Alan L

“…There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the…”
Get full text

[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma by Vos, Joris L., Zuur, Charlotte L., Smit, Laura A., de Boer, Jan Paul, Al-Mamgani, Abrahim, van den Brekel, Michiel W. M., Haanen, John B. A. G., Vogel, Wouter V.

“…Purpose To investigate the utility of [ 18 F]FDG-PET as an imaging biomarker for pathological response early upon neoadjuvant immune checkpoint blockade (ICB)…”
Get full text

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial by Vos, Joris L., Burman, Bharat, Jain, Swati, Fitzgerald, Conall W. R., Sherman, Eric J., Dunn, Lara A., Fetten, James V., Michel, Loren S., Kriplani, Anuja, Ng, Kenneth K., Eng, Juliana, Tchekmedyian, Vatche, Haque, Sofia, Katabi, Nora, Kuo, Fengshen, Han, Catherine Y., Nadeem, Zaineb, Yang, Wei, Makarov, Vladimir, Srivastava, Raghvendra M., Ostrovnaya, Irina, Prasad, Manu, Zuur, Charlotte L., Riaz, Nadeem, Pfister, David G., Klebanoff, Christopher A., Chan, Timothy A., Ho, Alan L., Morris, Luc G. T.

“…Salivary gland cancers (SGCs) are rare, aggressive cancers without effective treatments when metastasized. We conducted a phase 2 trial evaluating nivolumab…”
Get full text

Validation of a Machine Learning Model to Predict Immunotherapy Response in Head and Neck Squamous Cell Carcinoma by Lee, Andrew Sangho, Valero, Cristina, Yoo, Seong-Keun, Vos, Joris L, Chowell, Diego, Morris, Luc G T

“…Head and neck squamous-cell carcinoma (HNSCC) is a disease with a generally poor prognosis; half of treated patients eventually develop recurrent and/or…”
Get full text

CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors by Lei, Xin, de Groot, Daniël C., Welters, Marij J. P., de Wit, Tom, Schrama, Ellen, van Eenennaam, Hans, Santegoets, Saskia J., Oosenbrug, Timo, van der Veen, Annemarthe, Vos, Joris L., Zuur, Charlotte L., de Miranda, Noel F. C. C., Jacobs, Heinz, van der Burg, Sjoerd H., Borst, Jannie, Xiao, Yanling

“…CD4 + T cells can "help” or "license” conventional type 1 dendritic cells (cDC1s) to induce CD8 + cytotoxic T lymphocyte (CTL) anticancer responses, as proven…”
Get full text

Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma by van der Hulst, Hedda J, Vos, Joris L, Tissier, Renaud, Smit, Laura A, Martens, Roland M, Beets-Tan, Regina G H, van den Brekel, Michiel W M, Zuur, Charlotte L, Castelijns, Jonas A

“…Neoadjuvant immune checkpoint blockade (ICB) prior to surgery may induce early pathological responses in head and neck squamous cell carcinoma (HNSCC)…”
Get full text

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma by Vos, Joris L., Traets, Joleen J.H., Qiao, Xiaohang, Seignette, Iris M., Peters, Dennis, Wouters, Michel W.J.M., Hooijberg, Erik, Broeks, Annegien, van der Wal, Jacqueline E., Karakullukcu, M. Baris, Klop, W. Martin C., Navran, Arash, van Beurden, Marc, Brouwer, Oscar R., Morris, Luc G.T., van Poelgeest, Mariette I.E., Kapiteijn, Ellen, Haanen, John B.A.G., Blank, Christian U., Zuur, Charlotte L.

“…Mucosal melanoma (MucM) is a rare cancer with a poor prognosis and low response rate to immune checkpoint inhibition (ICI) compared with cutaneous melanoma…”
Get full text

Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637) by Zuur, Charlotte L., Elbers, Joris B. W., Vos, Joris L., van der Leun, Anne, Qiao, Xiaohang, Karakullukcu, Baris, van den Brekel, Michiel W. M., Tan, Bing, Jasperse, Bas, Vogel, Wouter V., Smit, Laura, Willems, Stefan M., van Tinteren, Harm, Al-Mamgani, Abrahim, Nijkamp, Jasper, Schumacher, Ton N., Blank, Christian U., De Boer, J. P., Haanen, John B. A. G.

“…Abstract only 2575 Background: surgery w/wo adjuvant radiotherapy (RT) for (recurrent) advanced head and neck squamous cell carcinoma (HNSCC) results in 30-50%…”
Get full text

Abstract 5786: Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer by Gil-Jimenez, Alberto, van Dijk, Nick, Lubeck, Yoni, van Montfoort, Maurits L., Peters, Dennis, Hooijberg, Erik, Broeks, Annegien, Vos, Joris L., Zuur, Charlotte L., van Rhijn, Bas, Vis, Daniel J., van der Heijden, Michiel S., Wessels, Lodewyk F.

“…Abstract Background: Immune checkpoint inhibitors (ICI) can achieve remarkable clinical responses in urothelial cancer (UC). However, it remains unclear which…”
Get full text

Abstract 2281: Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment by van der Leun, Anne M., Traets, Joleen J., Vos, Joris L., Elbers, Joris B., Patiwael, Sanne, Qiao, Xiaohang, Machuca-Ostos, Mercedes, Thommen, Daniela S., Haanen, John B., Schumacher, Ton N., Zuur, Charlotte L.

“…Abstract Immune checkpoint blockade has shown clinical activity in a range of cancer types. To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on…”
Get full text